Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63913 | 1.00 | KDM4E (0.51) | KDM4EPKMADORA3ADORA1ADORA2A | |
| SCHEMBL7899301 | 1.00 | KDM4E (0.51) | KDM4EPKMADORA3ADORA1ADORA2A | |
| SCHEMBL7751930 | 1.00 | KDM4E (0.51) | KDM4EPKMADORA3ADORA1ADORA2A | |
| SCHEMBL63914 | 1.00 | KDM4E (0.51) | KDM4EPKMADORA3ADORA1ADORA2A | |
| SCHEMBL1274810 | 0.86 | ADORA3 (0.51) | KDM4EPKMADORA3ADORA1 | |
| SCHEMBL1274809 | 0.86 | ADORA3 (0.51) | KDM4EPKMADORA3ADORA1 | |
| SCHEMBL1707366 | 0.86 | ADORA3 (0.51) | KDM4EPKMADORA3ADORA1 | |
| SCHEMBL29389281 | 0.86 | ADORA3 (0.51) | KDM4EPKMADORA3ADORA1 | |
| SCHEMBL28894185 | 0.86 | ADORA3 (0.54) | KDM4EPKMADORA3ADORA1 | |
| SCHEMBL28894183 | 0.86 | ADORA3 (0.54) | KDM4EPKMADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307434-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-06-04 | — | — | US | claimed |
| US-9744183-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2017-08-29 | — | — | US | claimed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| WO-2024112937-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER AND METABOLIC DISEASE | PRETZEL THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240175869-A1 | CHARACTERIZING THE BINDING INTERACTIONS BETWEEN MUSK AND BMP RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-30 | — | — | US | disclosed |
| US-20240174710-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| US-20240150756-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-09 | — | — | US | disclosed |
| US-20240132894-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-04-25 | — | — | US | disclosed |
| US-20240117347-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-04-11 | — | — | US | disclosed |
| EP-4346844-A1 | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | Apellis Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4344744-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-04-03 | — | — | EP | disclosed |
| EP-2370451-B1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES JAPAN INC (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-9394333-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | WAVE LIFE SCIENCES JAPAN (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20150211006-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20140194610-A1 | METHODS FOR THE SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS | WAVE LIFE SCIENCES PTE. LTD. (SG) | 2014-07-10 | — | — | US | disclosed |
| EP-2734208-A1 | METHODS FOR THE SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS | Wave Life Sciences Pte. Ltd. (SG) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013012758-A1 | METHODS FOR THE SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS | ONTORII, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | ONTORII, INC (US) | 2012-12-13 | — | — | US | disclosed |
| EP-2451461-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | Ontorii, Inc (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005761-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS USE THEREOF | ONTORII, INC (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | PNP, RNGTT, TYMP | KDM4E 3640/4885PKM 1487/4885ADORA3 159/4885 |
| US-20240132894-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | KDM4E 1901/4885PKM 2041/4885ADORA3 572/4885 |
| US-20240150756-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | KDM4E 2911/4885PKM 2582/4885ADORA3 1505/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | KDM4E 3578/4885PKM 4114/4885ADORA3 209/4885 |
| US-20140194610-A1 | METHODS FOR THE SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS | RNGTT, NUDT1, NSUN3 | KDM4E 4208/4885PKM 2095/4885ADORA3 2161/4885 |
| US-20240117347-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | KDM4E 2911/4885PKM 2582/4885ADORA3 1505/4885 |
| US-20150211006-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | KDM4E 3578/4885PKM 4114/4885ADORA3 209/4885 |
| US-20240174710-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | ALKBH1, DUT, RNGTT | KDM4E 2103/4885PKM 2769/4885ADORA3 261/4885 |
| US-10307434-B2 | Nucleic acid prodrugs and methods of use thereof | PNP, RNGTT, NSUN2 | KDM4E 3693/4885PKM 1754/4885ADORA3 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.